2
281
Scheme 4.
Reductive alkylation or sulfur-directed regioselective enolate formation followed by alkylation are
1
6
other attractive sequences. We are continuing to explore the synthetic possibilities of these cyclizations.
Acknowledgements
We thank the National Science Foundation and the Petroleum Research Fund (administered by the
American Chemical Society) for their financial support.
References
1
2
. Ponaras, A. A.; Zaim, Ö. Tetrahedron Lett. 1993, 34, 2879.
. Preparation of 6s: rxn of 2-bromo-2-cyclohexen-1-one with potassium 2-iodobenzyl thiolate in THF (cf., Fujisawa, T.;
Sakai, K.; Shirokata, H.; Fukushima, A. (Sagami Chemical Research Center) Jpn. Kokai Tokkyo Koho JP 54,088,210
(
1977) Chem. Abstr. 1979, 92, 76093c. Preparation of 10: heating 1,2-cyclohexanedione and 3-chloro-1-propanethiol in
benzene (cat. TsOH) under a Dean–Stark trap, followed by treatment with sodium iodide in acetone. Preparation of 13, 14,
7 and 21: rxn of 2,3-epoxycyclohexanone with the appropriate sodium thiolate in ethanol (cf., Tobias, M. A.; Strong,
1
J. G.; Napier R. P. J. Org. Chem. 1970, 35, 1709. Preparation of 18: rxn of 2,3-epoxycyclohexanone with sodium 2-
hydroxymethyl benzenethiolate in ethanol, followed by treatment with chlorotrimethylsilane/HMDS, followed by treatment
with iodotrimethylsilane.
3
4
. For a review of thiadecalins, see: Klimenko, S. K.; Stolbova, T. V. Usp. Khim. 1985, 54, 803.
. (a) Claus, P. K.; Rieder, W.; Vierhapper, F. W. Mh. Chem. 1978, 109, 609. (b) Vierhapper, F. W.; Willer, R. L. J. Org. Chem.
1
977, 42, 4024. (c) Claus, P. K.; Vierhapper, F. W.; Willer, R. L. J. Org. Chem. 1977, 42, 4016.
5
6
. Heterocyclic steroids: (a) Suginome, H.; Yamada, S.; Wang, J. B. J. Org. Chem. 1990, 55, 2170. (b) Ramadas, S. R.;
Chenchaiah, P. C.; Kumar, N. S. C.; Krishna, M. V.; Srinivasan, P. S.; Sastry, V. V. S. K.; Rao, J. A. Heterocycles 1982,
1
9, 861. (c) Huisman, H. O.; Speckamp, W. N. Int. Rev. Sci., Org. Chem., Ser. Two 1976, 8, 207.
. Heterocyclic inhibitors of terpenoid biosynthesis: (a) Bull, H. G.; Harris, G.; Myers, R. W. (Merck and Co., Inc.), US Patent
,756,480, (1996); Chem. Abstr. 1998, 129, 16283n. (b) Bakshi, R. K.; Patel, G. F.; Rasmusson, G. H.; Tolman, R. L. (Merck
5
and Co., Inc.), PCT Int. Appl. WO 97 15,564 (1997); Chem. Abstr. 1997, 127, 50846s.
. Heterocyclic prostaglandins: Orth, D.; Radunz, H. E. Top. Curr. Chem. 1977, 72, 51.
. Inter alia: (a) Giese, B. Angew. Chem., Int. Ed. Engl. 1983, 22, 753. (b) Viehe, H. G.; Merenyi, R.; Janousek, Z. Pure Appl.
Chem. 1988, 60, 1635.
7
8
9
. (a) Struble, D. A.; Beckwith, A. L.; Gream, G. A. Tetrahedron Lett. 1968, 3701. (b) Beckwith, A. L.; Schiesser, C. H.
Tetrahedron 1985, 41, 3925. (c) Spellmeyer, D. C.; Houk, K. N. J. Org. Chem. 1987, 52, 959.
1
1
0. All new compounds were fully characterized: 60 MHz H NMR (CDCl
6
3
) and IR (film) data are presented below. Compound
−1
s: NMR δ 1.7–2.7 (m, 6H), 3.98 (s, 2H), 6.79 (t, J=4.5 Hz, 1H), 6.9–8.0 (m, 4H); IR 1678, 1589, 1245, 1160 cm
Compound 7s: NMR δ 1.4–3.1 (m, 7H), 3.46 (d, J=12 Hz, 1H), 3.68 (s, 2H), 6.9–7.5 (m, 4H); IR 1715, 1654, 1541, 1489,
.
−
−
−
1
1
1
1
1
1
1
456 cm . Compound 10: NMR δ 1.7–3.0 (m, 10H), 3.27 (t, J=6.5 Hz, 2H), 6.80 (t, J=4.5 Hz, 1H); IR 1677, 1589, 1210,
1
125 cm . Compound 11: NMR δ 1.1–2.1 (m, 9H), 2.1–2.6 (m, 4H), 3.19 (d, J=9 Hz, 1H); IR (KBr) 1699, 1454, 1318,
1
122 cm . Compound 14: NMR δ 1.8–2.8, (m, 6H), 6.63 (t, J=4.5 Hz, 1H), 6.9–7.9 (m, 4H); IR 1680, 1590, 1421, 1330,
−
1
125, 1007 cm . Compound 15: NMR δ 1.6–2.7 (m, 6H), 3.4–4.0 (m, 1H), 4.27 (d, J=7, 1H), 6.7–7.4 (m, 4H); IR 1708,
−1
665, 1446, 1233 cm . Compound 17: NMR δ 1.6–2.7 (m, 6H), 6.53 (t, J=4.5 Hz, 1H), 7.1–7.6 (m, 4H); IR 1676, 1592,
−
1
440, 1346, 1262, 750 cm . Compound 18: NMR δ 1.7–2.8 (m, 6H), 4.63 (s, 2H), 6.28 (t, J=4.5 Hz, 1H) 6.9–7.5 (m, 4H);